(NYSE: BHVN) Biohaven's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.06%.
Biohaven's earnings in 2026 is -$647,677,000.On average, 20 Wall Street analysts forecast BHVN's earnings for 2026 to be -$461,077,976, with the lowest BHVN earnings forecast at -$503,144,716, and the highest BHVN earnings forecast at -$406,288,832. On average, 20 Wall Street analysts forecast BHVN's earnings for 2027 to be -$370,184,306, with the lowest BHVN earnings forecast at -$553,311,638, and the highest BHVN earnings forecast at -$252,475,724.
In 2028, BHVN is forecast to generate -$298,396,826 in earnings, with the lowest earnings forecast at -$467,732,772 and the highest earnings forecast at -$67,978,287.